Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

The US biotech saw a net loss last year despite increased sales and has decided to focus more on its wholly owned pipeline, which includes a safer formulation of a Roche pulmonary fibrosis product.

In 2020, In Vivo launched its annual Rising Leaders list to spotlight talent across the life sciences industry. The editorial team selected 30 individuals from across the biopharma, medtech, academic and healthtech sectors. Here we revisit the class of 2020 and see where they are now.

Becton Dickinson has formally completed the planned spin-off of its diabetes business within the timeframe it projected about a year ago. The new company, called embecta, is one of the largest producers of diabetes injection devices.